Abstract:Introduction: Morbidity and mortality associated with invasive fungal infections (IFIs) remains unacceptably high. Such diseases represent a substantial burden to the healthcare system. New options are needed to address antifungal resistance in existing and emerging pathogens and improve treatment outcomes while minimizing drug-related toxicities and interactions. Awareness of new and potential future options is of great value for those healthcare professionals who care for patients with IFIs. Areas covered: A search of PubMed, infectious diseases conference abstracts and reference lists from relevant publications was conducted and relevant information abstracted. This review describes the limitations of existing systemic antifungal therapies (e.g., resistance, drug-drug interactions, drug-related toxicities) and summarizes data regarding several emerging antifungal compounds including (but not limited to) new triazoles (e.g. isavuconazole, ravuconazole), echinocandins (e.g., aminocandin) and nikkomycin Z. Agents in clinical trials such as (but not limited to) new triazoles (e.g., isavuconazole, ravuconazole), echinocandins (e.g., aminocandin) and nikkomycin are included. New formulations of existing drugs including reformulations of miconazole, posaconazole and amphotericin B are also reviewed. Finally, new or novel administration strategies for existing drugs such as combination antifungal therapy, antifungal dose escalation, adjunctive use of iron chelators and preemptive therapy are discussed. Expert opinion: All present antifungal agents have some deficiencies in antifungal spectra, toxicity, pharmacokinetics and/or drug-drug interactions, making them less than ideal for some fungal infections. Therefore, there remains an urgent need to find safe, effective, rapidly fungicidal, broad-spectrum antifungal agents with excellent pharmacodynamics to effectively eliminate the fungus from the body with short antifungal courses.

New antifungal strategies: drug combination and co-delivery

Fungus-mediated Biosynthesis of Gold Nanoparticles with Synergistic Antifungal Activity Against Multidrug-Resistant Candida Albicans

Synergistic Combinations of Antifungals and Anti-Virulence Agents to Fight Againstcandida Albicans

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond.

Combination of antifungal therapy

Drug repurposing strategies in the development of potential antifungal agents

Combating Fungal Infections and Resistance with a Dual-Mechanism Luminogen to Disrupt Membrane Integrity and Induce DNA Damage

Optimising the Treatment of Invasive Candidiasis – A Case for Combination Therapy

Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox

The Effect of Ginkgolide B Combined with Fluconazole Against Drug-Resistant Candida Albicans Based on Common Resistance Mechanisms

Antifungal Effects of Phytocompounds on Candida Species Alone and in Combination with Fluconazole.

Old and new strategies in therapy and diagnosis against fungal infections

Strategies in the Discovery of Novel Antifungal Scaffolds

A Dual-Targeting Antifungal is Effective Against Multidrug-Resistant Human Fungal Pathogens

Antifungal activity of immunosuppressants used alone or in combination with fluconazole

Special Issue: Novel Antifungal Drug Discovery

A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species

Tackling multi-drug resistant fungi by efflux pump inhibitors

Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations

The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens